Bicyclic derivatives as CETP inhibitors

The compound of formula (I C)

• wherein X is N and Y is CH or N;
• R1 is 2-C1-C7-alkyl-2H-tetrazol-5-yl;
• the element —N(R4)(R5) is pyrrolidine-1-yl which is substituted by one or two substituents selected from the group consisting of C1-C7-alkyl-, C3-C7-cycloalkyl-, C3-C7-cycloalkyl-methyl-, C1-C7-alkoxy-methyl-, hydroxy-C1-C2-alkyl-C3-C7-cycloalkyl-, formyl-C3-C7-cycloalkyl-, formyl-C1-C2-alkyl-C3-C7-cycloalkyl-, HO2C—C3-C7-cycloalkyl-, HO2C—C1-C2-alkyl-C3-C7-cycloalkyl-, H2NC(═O)—C3-C7-cycloalkyl-, or H2NC(═O)—C1-C2-alkyl-C3-C7-cycloalkyl-;
• R9 is halogen;
• R12 and R13, independently of one another, is halo-C1-C7-alkyl or also halogen;
• wherein p is 1 or 2;
• or
• R4 is (C1-C4) alkyl- or (C3-C5) cycloalkyl-;
• and
• R5 is (C3-C7) cycloalkyl-(C1-C2) alkyl- which is optionally substituted by one to two substitutents selected from hydroxyl, alkoxy, HO2C—, HO2C—(C1-C3) alkyl-, hydroxy-(C1-C3) alkyl-, (C1-C6) alkoxy-carbonyl-, or (C1-C6) alkoxy-carbonyl-(C1-C3) alkyl-;
• or a salt thereof.